Logo

SaNOtize Reports Results of Nitric Oxide Nasal Spray in P-III Clinical Trial for the Treatment of COVID-19

Share this

SaNOtize Reports Results of Nitric Oxide Nasal Spray in P-III Clinical Trial for the Treatment of COVID-19

Shots:

  • The P-III trials evaluate NONS vs saline control in 306 patients with COVID-19 at 20 clinical sites across India
  • The results showed that NONS reduced the SARS-CoV-2 log viral load by ≥94% within 24hrs. & ≥99% in 48hrs. In the high-risk group, a greater proportion of patients achieved clinical & virological cure, the median time to negative PCR (4 days vs 8 days), was safe & well-tolerated
  • Glenmark has received CDSCO’s approval for NONS to treat COVID-19 & is expected to be available in India under the brand name FabiSpray. NONS has a marketing authorization as a Class I Medical Device in the EU & also approved in Israel, Thailand, Indonesia & Bahrain under the name enovid or VirX

Ref: Businesswire | Image: Clinical Trial Arena

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions